Circular Genomics, a New Mexico-based startup specializing in circular RNA biomarkers for neurology and psychiatry, has announced its move to the Lilly Gateway Labs innovation hub in San Diego. The company’s selection is based on its promising circRNA platform technologies and diagnostic programs targeting neurological disorders like Alzheimer’s disease. In partnership with Eli Lilly and Alexandria Real Estate Equities Inc., the collaboration aims to advance Alzheimer’s biomarkers and improve disease identification and monitoring.
Circular Genomics recently launched MindLight, a blood test designed to predict responses to antidepressant treatment in patients with major depressive disorder. The move to Gateway Labs marks a key growth milestone, following an $8.3 million Series A funding round, which will support hiring and product development.
See Molly Callaghan’s March 19 article, “ABQ startup Circular Genomics relocates to San Diego,” on the New Mexico Inno website here: https://www.bizjournals.com/albuquerque/inno/stories/news/2025/03/19/abq-startup-moves-hq-to-san-diego.html